Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy
MP Hamilton, T Sugio, T Noordenbos… - … England Journal of …, 2024 - Mass Medical Soc
Background The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy,
especially the risk of T-cell neoplasms related to viral vector integration, is an emerging …
especially the risk of T-cell neoplasms related to viral vector integration, is an emerging …
Decoding Cancer Evolution: Integrating Genetic and Non-Genetic Insights
The development of cancer begins with cells transitioning from their multicellular nature to a
state akin to unicellular organisms. This shift leads to a breakdown in the crucial regulators …
state akin to unicellular organisms. This shift leads to a breakdown in the crucial regulators …
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management
Genetically engineered chimeric antigen receptor (CAR) T cells have become an effective
treatment option for several advanced B-cell malignancies. Haematological side-effects …
treatment option for several advanced B-cell malignancies. Haematological side-effects …
[HTML][HTML] A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells
S Turkalj, NA Jakobsen, A Groom, FA Radtke, P Vyas - STAR protocols, 2023 - Elsevier
Single-cell assay for transposase-accessible chromatin with sequencing (scATAC-seq)
resolves the heterogeneity of epigenetic states across cells but does not typically capture …
resolves the heterogeneity of epigenetic states across cells but does not typically capture …
Identification of a human hematopoietic stem cell subset that retains memory of inflammatory stress
Inflammation activates many blood cell types, driving aging and malignancy. Yet,
hematopoietic stem cells (HSCs) survive a lifetime of infection to sustain life-long blood …
hematopoietic stem cells (HSCs) survive a lifetime of infection to sustain life-long blood …